The severe winter storm Fern, leaving nearly a million customers without power, has starkly highlighted the U.S. electrical grid's persistent vulnerabilities. This comes despite repeated warnings from reliability monitors about the system's growing strain.
Clinical-stage biotech Erasca (ERAS) has seen its stock skyrocket over the past 12 months, hitting a multi-year high. While technical momentum is strong, the company remains pre-revenue, with its fate tied to future drug approvals, presenting a classic high-risk, high-reward scenario for investors.
As Palantir Technologies prepares to report Q4 results, soaring demand for its AI platform collides with sky-high valuations, leaving investors to weigh robust growth against bubble fears.
Expedia Group stock rose sharply after announcing an expanded, exclusive partnership with Affirm, making the fintech firm the sole 'Buy Now, Pay Later' provider across its major U.S. travel platforms.
In an unusual acquisition within the ETF space, the investment arm behind former President Donald Trump's social media platform is set to purchase the conservative-themed 'God Bless America' ETF, significantly expanding its asset base and adding active management to its lineup.
Franklin Templeton has launched the Templeton Emerging Markets Debt ETF (TEMD), aiming to give investors targeted exposure to both hard and local currency debt from developing economies, capitalizing on the asset class's recent strong performance.
Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.
UPS's ambitious free cash flow target for 2026 appears to secure its hefty dividend, but a closer look reveals reliance on asset sales, deep cost cuts, and reduced capital investment—a strategy that may be mortgaging its long-term expansion.
The narrative around Chinese electric vehicles is undergoing a fundamental shift. Once known primarily for affordability, leading Chinese automakers are now challenging incumbents with rapidly improving quality, technology, and reliability, forcing a global industry recalibration.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
Morgan Stanley's top strategist argues that recent U.S. trade shifts have prompted nations worldwide to reassess and leverage their own economic strengths, creating a multi-year investment opportunity in a more multipolar global order.
CNBC's Jim Cramer endorsed Carrier Global Corp. (NYSE:CARR) on his recent show, praising CEO Dave Gitlin's leadership and strategic acquisition. He recommended investors buy the stock for the long term, citing confidence in the company's positioning within the climate solutions sector.
CNBC's Jim Cramer expressed reservations about aviation services provider AAR Corp., highlighting its 15% gross yield as a potential red flag for investors during a recent market analysis segment.
CNBC's Jim Cramer reaffirmed his bullish stance on Rio Tinto, highlighting the mining giant's role as a strategic hedge against geopolitical and economic volatility during the show's Lightning Round.
CNBC's Jim Cramer highlighted International Business Machines Corp. (IBM) as a standout AI investment with a relatively modest valuation, following a robust quarterly report that sent shares soaring.
CNBC's Jim Cramer spotlighted Royal Caribbean Cruises Ltd. (RCL) this week, praising its ambitious full-year 2026 forecast as the cruise line capitalizes on robust post-pandemic demand and operational efficiencies.
CNBC's Jim Cramer positions Alphabet as the potential 'only winner in AI,' suggesting its upcoming earnings may show it generating more revenue from AI than rival Meta Platforms.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
A second major winter storm in as many weeks has crippled logistics across the Southeast, leading to massive service suspensions, a deadly 100-car pileup, and worsening a freight backlog that saw volumes plummet over 55%.
